HENRY A. WAXMAN, CALIFORNIA EDWARD J. MARKEY, MASSACHUSETTS RICK BOUCHER, VIRIGINIA EDOLPHUS TOWNS, NEW YORK FRANK PALLONE, J.M., NEW JERSEY BART GORDON, TENNESSEE BOBBY L. RUSH, ILLINOIS ANNA G. ESHOO, CALIFORNIA BART STUPAK, MICHIGAN ELIOT L. ENGEL, NEW YORK ALBERT R. WYNN, MARYLAND GENE GREEN, TEXAS DIANA DEGETTE. COLORADO VICE CHAIRMAN LOIS CAPPS, CALIFORNIA MIKE DOYLE, PENNSYLVANIA JANE HARMAN, CALIFORNIA TOM ALLEN, MAINE JAN SCHAKOWSKY, ILLINOIS HILDA L. SOLIS, CALIFORNIA CHARLES, GONZALEZ, TEXAS JAY INSLEE, WASHINGTON TAMMY BALDWIN, WISCONSIN MIKE ROSS, ARKANSAS DARLENE HOOLEY, OREGON ANTHONY D. WEINER, NEW YORK JIM MATHESON, UTAH G.K. BUTTERFIELD, NORTH CAROLINA CHARLES REFIELD NORTH CAROLINA CHARLES REFIELD, NORTH CAROLINA CHARLE MELANCON, LOUISIANA JOHN BARROW, GEORGIA BARON, HILLI, LIDILINA

DENNIS B. FITZGIBBONS, CHIEF OF STAFF GREGG A. ROTHSCHILD, CHIEF COUNSEL ONE HUNDRED TENTH CONGRESS

U.S. House of Representatives Committee on Energy and Commerce Washington, DC 20515-6115

JOHN D. DINGELL, MICHIGAN CHAIRMAN

April 12, 2007

JOE BARTON, TEXAS
AMKING MEMBER
RALPH M. HALL, TEXAS
J. DENNIS HASTERT, ILLINOIS
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
NATHAN DEAL, GEORGIA
ED WHITHELD, KENTUCKY
BARBARA CUBIN, WYOMING
JOHN SHIMKUS, ILLINOIS
HEATHER WILSON, NEW MEXICO
JOHN B. SHADEGG, ARIZONA
CHARLES W. "CHIP" PICKERING, MISSISSIPPI
VITO FOSSELLA, NEW YORK
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R. PITTS, PENNSYLVANIA
MARY BONO, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE FERGUSON, NEW JERSEY
MIKE ROGERS, MICHIGAN
SUE MYRICK, NORTH CAROLINA
JOHN SULLIVAN, OKLAHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. BURGESS, TEXAS
MARSHA BLACKBURN, TENNESSEE

The Honorable Andrew von Eschenbach, M.D. Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

VIA FAX

Dear Dr. von Eschenbach:

Pursuant to Rules X and XI of the Rules of the U.S. House of Representatives, the Committee on Energy and Commerce and the Subcommittee on Oversight and Investigations have opened an inquiry into compensation practices at the Food and Drug Administration (FDA).

In particular, we are interested in FDA's use of Title 42 consultant compensation and other mechanisms to boost compensation above base salary including retention bonuses, locality bonuses, performance, or any other salary enhancements or awards. Please provide the following information within two weeks of receipt of this letter:

1. A list of all current FDA employees and their positions enjoying higher total compensation (includes salary, bonuses, cash awards or other cash enhancements) than the highest Senior Executive Service (SES) salary grade or the salary of an Admiral in the Public Health Service (currently \$168,120 per annum) if in a senior management position, or the highest General Schedule (GS) salary grade (currently \$154,600) if paid under the GS scales. For each such individual for each year from calendar year 2002 forward, please provide the annual compensation and the mechanism of compensation (Title 42, Commissioned Corps, SES, physician comparability allowance, etc.). For all such employees compensated under Title 42, please also list the date of their appointment.

The Honorable Andrew von Eschenbach, M.D. Page 2

2. A list of all FDA employees, regardless of total compensation, and their positions who have received retention, locality, performance bonuses or awards, or other extraordinary payments in excess of \$5,000 in any given year and the amounts of such bonuses, awards, or other extraordinary payments since January 1, 2002.

Please also provide the records justifying the bonuses, awards, or other extraordinary payments. For the purpose of responding to this request for information and documents, the terms "records" and "relating" should be interpreted in accordance with the attachment to this letter. If you have any questions, please contact David Nelson of the Majority Committee staff at (202) 226-2424 or Alan Slobodin of the Minority Committee staff at (202) 225-3641.

Sincerely,

John D. Dingell Chairman

Joe Barton

Ranking Member

Bart Stupak

Chairman

Subcommittee on Oversight and Investigations

Ed Whitfield

Ranking Member

Subcommittee on Oversight and Investigations

Attachment

ATTACHMENT

- 1. The term "records" is to be construed in the broadest sense and shall mean any written or graphic material, however produced or reproduced, of any kind or description, consisting of the original and any non-identical copy (whether different from the original because of notes made on or attached to such copy or otherwise) and drafts and both sides thereof, whether printed or recorded electronically or magnetically or stored in any type of data bank, including, but not limited to, the following: correspondence, memoranda, records, summaries of personal conversations or interviews, minutes or records of meetings or conferences, opinions or reports of consultants, projections, statistical statements, drafts, contracts, agreements, purchase orders, invoices, confirmations, telegraphs, telexes, agendas, books, notes, pamphlets, periodicals, reports, studies, evaluations, opinions, logs, diaries, desk calendars, appointment books, tape recordings, video recordings, emails, voice mails, computer tapes, or other computer stored matter, magnetic tapes, microfilm, microfiche, punch cards, all other records kept by electronic, photographic, or mechanical means, charts, photographs, notebooks, drawings, plans, inter-office communications, intra-office and intra-departmental communications, transcripts, checks and canceled checks, bank statements, ledgers, books, records or statements of accounts, and papers and things similar to any of the foregoing, however denominated.
- 2. The terms "relating," or "relate" as to any given subject means anything that constitutes, contains, embodies, identifies, deals with, or is in any manner whatsoever pertinent to that subject, including but not limited to records concerning the preparation of other records.